RT Journal Article
T1 Glucosinolate-Degradation Products as Co-Adjuvant Therapy on Prostate Cancer in Vitro
A1 Núñez Iglesias, María Jesús
A1 Novío Mallón, Silvia
A1 García Santiago, Carlota
A1 Pérez Muñuzuri, Mª Elena
A1 Soengas Fernández, María del Pilar
A1 Cartea González, María Elena
A1 Velasco Pazos, Pablo
A1 Freire-Garabal Núñez, Manuel
K1 Chemoprevention
K1 Docetaxel
K1 Drug-sensitization
K1 Isothiocyanates
K1 Prostate cancer
K1 Synergism
AB Glucosinolate-degradation products (GS-degradation products) are believed to be responsible for the anticancer effects of cruciferous vegetables. Furthermore, they could improve the efficacy and reduce side-effects of chemotherapy. The aim of the present study was to determine the cytotoxic effects of GS-degradation products on androgen-insensitive human prostate cancer (AIPC) PC-3 and DU 145 cells and investigate their ability to sensitize such cells to chemotherapeutic drug Docetaxel (DOCE). Cells were cultured under growing concentrations of allyl-isothiocyanate (AITC), sulforaphane (SFN), 4-pentenyl-isothiocyanate (4PI), iberin (IB), indole-3-carbinol (I3C), or phenethyl-isothiocyanate (PEITC) in absence or presence of DOCE. The anti-tumor effects of these compounds were analyzed using the trypan blue exclusion, apoptosis, invasion and RT-qPCR assays and confocal microscopy. We observed that AITC, SFN, IB, and/or PEITC induced a dose- and time-dependent cytotoxic effect on PC-3 and DU 145 cells, which was mediated, at least, by apoptosis and cell cycle arrest. Likewise, we showed that these GS-degradation products sensitized both cell lines to DOCE by synergic mechanisms. Taken together, our results indicate that GS-degradation products can be promising compounds as co-adjuvant therapy in prostate cancer.
PB MDPI
YR 2019
FD 2019
LK http://hdl.handle.net/10347/21414
UL http://hdl.handle.net/10347/21414
LA eng
NO Núñez-Iglesias, M. J., Novío, S., García, C., Pérez-Muñuzuri, E., Soengas, P., Cartea, E., . . . Freire-Garabal, M. (2019). Glucosinolate-degradation products as co-adjuvant therapy on prostate cancer in vitro. International Journal of Molecular Sciences, 20(20), 4977. doi:10.3390/ijms20204977
NO This research was supported by the Spanish National Plan for Research and Development, grant number AGL2012-9 35539, and financed by the European Regional Development Funds (FEDER)
DS Minerva
RD 28 abr 2026